{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-124829","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2026-11-10T13:21:10+00:00","discovered_at":"2026-11-10T13:25:00.297435+00:00","generated_at":"2026-11-10T13:25:07.248441+00:00","sec_items":["1.01","2.02","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MaxCyte to acquire Akron Bio for $151.8M; Q3 revenue up 49% to $10.2M","bullets":["Deal: $105M cash + 20,639,733 MXCT shares (~$26.8M) + $20M deferred ($10M each in Jan 2028 and Jan 2029); total $151.8M.","Akron Bio expected 2026 revenue ~$28M and EBITDA $7-8M; products embedded in five approved therapies and >100 clinical programs.","Q3 2026 revenue $10.2M (+49% YoY): core $8.2M (+27%), SPL $2.0M vs $0.4M; gross margin 83%; net loss $4.8M vs $12.4M.","FY2026 revenue guidance raised to at least $34.5M (core ~$28M, SPL at least $6.5M); cash $132.7M at Sept 30.","MidCap facility up to $75M; expects $22M drawn at close. Deal needs HSR and Nasdaq listing approval, no stockholder vote; targeted before end-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-124829","json":"https://secwatch.observer/filing/0001104659-26-124829.json","markdown":"https://secwatch.observer/filing/0001104659-26-124829.md","text":"https://secwatch.observer/filing/0001104659-26-124829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000110465926124829/0001104659-26-124829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000110465926124829/tm2629420d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T13:25:07.248441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}